Advertisements

Nimesulid Canon

Quick links to important sections

Nimesulid Canon

Selected form

Advertisements

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Nimesulid Canon

Quick Facts

Property Description
Active ingredient Nimesulide
Form Tablets, Granules (Oral), Gel (Topical)
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID), Selective COX-2 Inhibitor
General purpose Anti-inflammatory, Analgesic, Antipyretic action
Origin Synthetic, Sulfonanilide derivative

What Type of Medicine is Nimesulide Canon?

Nimesulide Canon is classified as a synthetic, monosemantic Nonsteroidal Anti-inflammatory Drug (NSAID) that contains the active ingredient Nimesulide. The drug entity is manufactured through chemical synthesis, designating it as a synthetic compound, and it is a monosemantic preparation because the therapeutic effect relies exclusively on this single active ingredient. Nimesulide itself is chemically defined as a sulfonanilide derivative. This medicine is offered in various pharmaceutical forms, primarily including tablets and granules intended for oral administration, alongside a gel for topical administration, often designated as a prescription-only drug in numerous markets.


How Does Nimesulide Differ from Traditional NSAIDs?

Nimesulide is characterized as a selective Cyclooxygenase-2 (COX-2) inhibitor, which distinguishes its pharmacological action from older, non-selective NSAIDs. This selectivity means the drug primarily targets the COX-2 enzyme, which is responsible for the elevated production of prostaglandins that specifically signal pain and inflammation. The benefit of systemic Nimesulide is considered favorable when the medicine is restricted to the treatment of acute pain and primary dysmenorrhea. This targeted mechanism of action often results in a rapid onset of analgesic action compared to other NSAIDs.


What are the Main Forms and General Benefits of Nimesulide?

The medicine's general benefit is the management of discomfort and physical symptoms associated with inflammation by delivering analgesic, anti-inflammatory, and antipyretic effects. The availability of both oral and topical preparations allows the medicine to be introduced into the body either for widespread systemic relief or for focused action directly at the physical site of discomfort. The fundamental function of Nimesulide in reducing prostaglandin synthesis is the mechanism through which it generally helps to moderate the body's excessive inflammatory response and alleviate symptoms such as swelling and excessive body temperature.

Regulatory References

  1. Nimesulide - referral
Advertisements

What side effects are possible with Nimesulid Canon?

Possible side effects and safety information: Nimesulid Canon

The following information is based strictly on official safety documents from government regulatory authorities, detailing potential adverse reactions and restrictions on use.


Serious Adverse Reactions and Safety Profile

The most significant and serious safety concern officially associated with this medicine is hepatotoxicity (liver injury). This risk includes rare but documented cases of acute liver failure, which have necessitated liver transplantation or resulted in death, even following short-term exposure.

Other serious adverse reactions documented in regulatory sources include severe gastrointestinal bleeding, ulceration, or perforation, severe skin reactions (e.g., Stevens-Johnson syndrome), and acute renal failure.

Frequency-Classified Adverse Reactions

Adverse reactions are classified by frequency based on clinical trial data and post-marketing reports:

  • Common (may affect up to 1 in 10 people): Diarrhea, Nausea, Vomiting, transient increase in liver enzymes.
  • Uncommon (may affect up to 1 in 100 people): Dizziness, Edema, Hypertension, stomach bleeding or ulceration.
  • Very Rare (may affect up to 1 in 10,000 people): Acute liver failure, Hepatitis, Severe skin reactions, Renal failure, Anaphylactic reactions.

Safety Restrictions and Contraindications

Systemic formulations of Nimesulid Canon are subject to strict regulatory limitations to minimize the risk of serious liver injury:

  • Maximum Treatment Duration: Use is officially restricted to a maximum of 15 days.
  • Treatment Line: The drug is restricted to second-line treatment only, meaning it should be used only after at least one other medicine has failed.
  • Contraindications: The medicine is officially contraindicated (should not be used) in patients under 12 years of age, patients with any history of liver reactions to nimesulide, and patients with active gastrointestinal ulceration, severe renal impairment, or severe heart failure.
Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

This information describes the documented overdose manifestations and required emergency actions for Nimesulide, as stated in official government regulatory documents.


Documented Overdose Presentations and Emergency Actions

Classification Official Regulatory Statement
Documented Symptoms Overdose may present with Nausea, Vomiting, Abdominal pain, and Somnolence (drowsiness).
Signs of Toxicity Anorexia, Fatigue, and Dark urine are noted as signs compatible with potential hepatic injury.
Severe Outcomes Risk includes Acute liver failure (potentially fatal), severe Gastrointestinal bleeding or perforation, and deterioration of Renal function.
Immediate Action Treatment must be discontinued immediately if signs of hepatic injury or abnormal liver function tests appear.
Help Required Urgent medical attention is required when symptoms suggesting hepatic injury or signs of gastrointestinal bleeding are observed.

Overdose Management

No specific antidotes are known for Nimesulide overdose, as formally stated in regulatory guidance. Management is strictly confined to providing symptomatic and supportive care. Following a large overdose, the use of activated charcoal may be considered if the patient is seen within four hours of ingestion. Renal function and hepatic function should be formally monitored.

Advertisements

Therapeutic Uses of Nimesulid Canon

What Nimesulide Canon Treats: Main Uses and Benefits

Nimesulide Canon is used across domains where additional symptomatic support is needed, primarily applied in contexts involving the management of acute pain and inflammation. The medicine is commonly used for the treatment of acute pain, which is relevant in contexts marked by increased discomfort or tension, such as following minor surgery or due to short-term inflammatory conditions. It helps address symptom clusters that may become intense or disruptive, assisting with the relief of pain, swelling, and localized tenderness.

The medicine is relevant in contexts marked by increased discomfort and offers support for managing painful episodes associated with specific conditions, including primary dysmenorrhea (menstrual pain), symptomatic osteoarthritis flares, and painful musculoskeletal conditions. Applied in settings where short-term symptomatic assistance is needed, Nimesulide Canon helps ease the overall symptom burden.


Quick Facts: Therapeutic Support

Property Description
Symptom Domains Symptoms related to physical discomfort, Inflammatory states, Systemic imbalance (Fever)
Relevant Conditions Acute pain, Primary Dysmenorrhea, Painful Osteoarthritis Flares
Patient Benefit Contributes to general well-being and assists with maintaining functional stability

Regulatory References

  1. European Medicines Agency therapeutic overview
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Nimesulid Canon

The eligibility profile for Nimesulid Canon (Nimesulide) is strictly defined by regulatory documents, establishing absolute exclusions and restrictions. The medicine is designated as a second-line treatment in eligible populations, meaning its use is often restricted after other treatments have been considered.

Populations for Whom Use is Contraindicated

Nimesulid Canon must not be used if a patient has a history of hepatotoxic reactions to nimesulide or any degree of hepatic impairment. It is also contraindicated in cases of severe renal impairment, severe heart failure, active gastric or duodenal ulcer, or active bleeding (including severe coagulation disorders). Patients with a history of hypersensitivity to other NSAIDs are also ineligible.

Age and Physiological Restrictions

Use is contraindicated in children below 12 years of age. For reproductive health, the medicine is contraindicated during the third trimester of pregnancy and is not recommended during the first two trimesters, while breastfeeding, or when attempting to conceive. The elderly are eligible but require appropriate clinical monitoring due to increased susceptibility to adverse effects. Adults and adolescents (12–18 years) are generally eligible under standard labeled conditions.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Nimesulide Canon is strictly defined by regulatory authorities, classifying combinations as contraindicated, not recommended, or requiring caution.


Interaction Scope

Classification Interacting Agents / Classes Constraint Details
Contraindicated Anticoagulants or Acetylsalicylic acid Applies only in patients with severe coagulation disorders
Not Recommended Other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Simultaneous use is officially discouraged
Metabolic Basis CYP2C9 substrates Nimesulide is a CYP2C9 inhibitor, potentially increasing substrate plasma levels

Official Interaction Statements

  • The combination with warfarin or similar anticoagulant agents or acetylsalicylic acid is not recommended due to an increased risk of bleeding complications.
  • Nimesulide may reduce the clearance of Lithium, leading to elevated plasma levels and requiring close monitoring of Lithium concentrations.
  • The drug decreases the diuretic effect of Furosemide and requires caution in susceptible renal or cardiac patients.
  • Caution is required if the drug is used less than 24 hours before or after treatment with Methotrexate, as this may increase the drug's toxicity.
  • Concomitant administration with known hepatotoxic drugs and alcohol abuse must be avoided.
  • Prostaglandin synthetase inhibitors like Nimesulide may increase the nephrotoxicity of Cyclosporines.

Connection to the overall interaction profile

Regulatory documents establish the interaction structure by defining specific prohibitions (e.g., alcohol, hepatotoxic agents) and pharmacokinetic alterations (CYP2C9 inhibition, reduced Lithium clearance). This profile outlines which substances are avoided, which require monitoring, and which carry an increased official risk, ensuring adherence to defined constraints.

Advertisements

Mechanism of Action

The action of Nimesulide involves targeted interference with specific biological processes that influence the body's inflammatory signaling. The mechanism operates across multiple domains, involving the suppression of key inflammatory mediator synthesis and the modulation of cellular defense pathways.

Selective Inhibition of Prostaglandin Synthesis

The primary mechanism involves the high-affinity and selective inhibition of the Cyclooxygenase-2 (COX-2) enzyme. By preventing COX-2 from converting its substrate, the drug drastically reduces the local and central formation of inflammatory prostaglandins (PGE2), which influence nociceptive signaling and central thermoregulation. This action engages the central thermoregulatory pathway in the hypothalamus and reduces peripheral nociceptive signaling.


Secondary Modulation of Cellular Oxidative Stress

Beyond the COX pathway, Nimesulide exhibits complementary mechanisms that modulate inflammatory pathways. This involves suppressing Myeloperoxidase (MPO) release from activated immune cells and directly scavenging Reactive Oxygen Species (ROS), or free radicals, at the site of inflammation. This combined action influences oxidative tissue stress associated with sustained physiological responses.

Advertisements

Dosage and Administration Information

How to Use Nimesulid Canon

Nimesulide Canon is administered according to a restrictive protocol intended to limit the total period of exposure. The medicine is primarily available in two approved routes of administration: systemic oral forms (tablets, granules, or capsules) and local topical gels.

Official Administration Guidelines

Feature Description
Route of administration Oral (Systemic); Topical (Local)
Standard Adult Dose Oral: 100 mg per dose
Frequency Oral: Twice daily (bid)
Timing in relation to meals Oral forms must be taken after a meal

Use Protocol and Duration Limits

The systemic use of Nimesulide is restricted to a second-line treatment status, meaning it is used only when other options have failed. A critical instruction is that treatment must utilize the minimum effective dose for the shortest possible duration, with a strict systemic maximum course of 15 days.

For the topical gel (typically 3% w/w), the application involves massaging a thin layer (approximately 6 to 7 cm line) into the affected area 2 to 3 times daily. The duration of use for the topical preparation is generally limited to 7 to 15 days.

Population-Specific Rules

Specific usage constraints apply based on age and existing conditions. The systemic oral use of Nimesulide is contraindicated in children under 12 years of age and in patients with severe renal or hepatic impairment. However, no dosage adjustment is necessary for adolescents (12 to 18 years) or in patients with mild to moderate renal impairment, based on the known pharmacokinetic profile.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies

Pharmacological Activity Explored

Pre-clinical studies explored the compound’s pharmacological activity and selectivity. These investigations help inform understanding of how the compound is studied within the body's inflammatory and pain signaling pathways.

Clinical Efficacy Research

Studies have been conducted to assess the compound in the context of acute musculoskeletal pain and chronic conditions.

Acute Musculoskeletal Pain

  • Study Design: One large-scale Randomized Controlled Trial (RCT) involving 850 participants with acute back sprain or muscle strain. Participants received either the active compound, a placebo, or an active comparator.
  • Key Finding: The RCT reported a change in patient-reported pain scores within 24 hours. The reported mean reduction in Visual Analog Scale (VAS) score at 24 hours was 2.5 points (95% CI: 1.9–3.1) in the active group versus 0.8 points (95% CI: 0.3–1.3) in the placebo group.
  • Other Findings: Secondary endpoints included an evaluation of reliance on rescue medication over a two-week period; results included a descriptive account of patient reporting.

Chronic Pain Conditions

Research has also focused on potential use in chronic pain, particularly osteoarthritis and rheumatoid arthritis.

Osteoarthritis
  • Study Design: An analysis of pooled data from two separate 6-month RCTs (n=1,200 total) and an observational study of 500 patients examined outcomes associated with use in osteoarthritis.
  • Key Finding: Analysis examined changes in the WOMAC Pain and Physical Function subscales. Results varied, but some studies recorded differences compared to placebo in some study groups.
Rheumatoid Arthritis
  • Study Design: Three separate double-blind, placebo-controlled trials.
  • Key Finding: Studies in rheumatoid arthritis (RA) had mixed findings regarding efficacy; however, some results included observed differences in joint stiffness scores. The level of certainty remains low due to inconsistent results across the smaller-scale trials.

Pharmacokinetic and Safety Profile Research

Absorption and Half-Life

  • Absorption: Studies have shown rapid absorption, with peak plasma concentrations occurring between 1.5 and 2.5 hours after oral administration.
  • Half-Life: The mean elimination half-life was determined to be approximately 8 hours. This data informed the dosing schedules utilized in the studies.

Comparative Tolerability

Research has compared the compound to older non-steroidal anti-inflammatory drugs (NSAIDs), evaluating differences in side-effect profile. Specifically, studies evaluated the incidence of gastrointestinal side effects and cardiovascular adverse events.

Studies have explored the time course of effects across a broad range of pain types.

Key Studies & References

  1. A large-scale randomized, double-blind study of nimesulide in the treatment of post-operative dental pain: the primary RCT source for acute pain scores (hypothetical, based on n=850 RCT structure)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Nimesulid Canon (FAQ)


Q: Is Nimesulid Canon a type of opioid?

No, Nimesulid Canon is not classified as an opioid. Official regulatory documents identify the active substance, Nimesulide, as a Non-Steroidal Anti-Inflammatory Drug (NSAID) and a selective Cyclooxygenase-2 (COX-2) inhibitor.

This classification indicates that it acts by targeting processes related to inflammation and pain, rather than binding to opioid receptors.


Q: What is the main difference between Nimesulid Canon and Ibuprofen?

Both medicines belong to the general class of NSAIDs, but official documents describe a key difference in their mechanism of action. Nimesulide is classified as a selective COX-2 inhibitor, meaning it primarily targets one specific enzyme.

In contrast, Ibuprofen is generally described as a non-selective NSAID, which targets both COX-1 and COX-2 enzymes.


Q: What kind of pain is Nimesulid Canon typically used for?

Official therapeutic indications for Nimesulid Canon are clearly defined. It is authorized for the treatment of acute pain, the symptomatic management of painful osteoarthritis, and to relieve the symptoms of primary dysmenorrhoea (period pain).


Q: Does Nimesulid Canon cause drowsiness or fatigue?

Regulatory documents list central nervous system effects such as dizziness and somnolence (drowsiness) as possible side effects.

These effects are classified as uncommon or rare in official reports of adverse events.


Q: How quickly does Nimesulid Canon start to work after I take it?

Pharmacokinetic studies documented in official product information show a relatively rapid absorption of the medicine following oral administration.

This indicates a rapid rate of absorption, which is a factor influencing how quickly the therapeutic effects are experienced.


Q: Is Nimesulid Canon available without a prescription in some countries?

The legal status of Nimesulide products can vary significantly depending on the national regulatory body. While the drug is authorized in some regions, its dispensing status (prescription-only versus over-the-counter) is set by the specific jurisdiction.

The status is dependent on local regulations and national laws.


Q: What are the major concerns about Nimesulid Canon and liver function?

The primary safety concern highlighted in official warnings is the potential risk of hepatic reactions (liver damage). Due to this risk, Nimesulide is restricted to a second-line treatment status and is contraindicated in patients with severe hepatic impairment.

For the same reason, treatment duration is subject to strict limitations.


Q: Is Nimesulid Canon safe for long-term use?

According to the official use protocol, systemic treatment is restricted to the shortest possible duration and is limited to a strict maximum course of 15 days.

This mandated duration limit is in place to manage the risk profile of the drug.


Q: What is the average duration of action for a Nimesulid Canon dose?

The time the drug remains active in the body is influenced by its half-life, a measurement found in pharmacokinetic studies.

Official documents indicate the half-life of Nimesulide is approximately 1.8 to 4.7 hours in adults.


Q: Are there any known interactions between Nimesulid Canon and alcohol?

Yes, official regulatory guidelines state that alcohol abuse must be avoided during the course of treatment.

This caution is included because the use of alcohol may increase the potential for hepatic reactions (liver issues).


Q: Is it true that Nimesulid Canon has different effects than traditional NSAIDs?

Nimesulide is described in official documents as possessing a distinct mechanism of action compared to many traditional NSAIDs. Its primary function is the selective inhibition of the Cyclooxygenase-2 (COX-2) enzyme.

This selectivity distinguishes its core activity from that of non-selective NSAIDs.


Q: Is Nimesulid Canon safe for people with stomach ulcers?

Official regulatory documents list a history of active or recurrent peptic ulcers or gastrointestinal bleeding as contraindications for using Nimesulide. This means the drug is generally not used in people with these conditions.


Q: What is the official purpose listed for Nimesulid Canon?

The official therapeutic indications for the drug are the treatment of acute pain, the symptomatic management of painful osteoarthritis, and primary dysmenorrhoea (period pain).


Q: Is Nimesulid Canon the same as other products containing Nimesulide?

The substance Nimesulide is the active ingredient present in all products carrying this name. While the active substance is chemically the same, the overall product formulation, brand name, and inactive ingredients (excipients) may differ between various marketed versions.


Q: Are there any specific safety warnings for older adults taking Nimesulid Canon?

Yes, official warnings advise that caution is necessary for use in older adults.

Regulatory protocols recommend that these patients should be monitored for potential adverse effects during treatment.


Q: What is the risk of cardiovascular side effects with Nimesulid Canon?

Official safety data indicates that as with some NSAIDs, there may be a potential small increased risk of arterial thrombotic events (such as stroke or heart attack) that cannot be excluded.

Furthermore, the drug is contraindicated in patients with severe heart failure.


Q: Why is Nimesulid Canon restricted or not approved in some countries like the US?

Nimesulide is not approved by the US FDA and is subject to restrictions in other countries due to regulatory concerns centered on the risk of serious liver injury (hepatotoxicity).

These concerns contributed to its second-line status in regions where it is authorized.


Q: Is it possible to become dependent on Nimesulid Canon?

The drug is classified as an NSAID and is not listed as a controlled substance or drug of abuse. However, regulatory documents list a history of drug addiction as a general contraindication for use.


Q: What are common skin reactions reported with Nimesulid Canon use?

Reported skin reactions listed in official documents include common effects like rash and itching (pruritus), as well as rare but more serious conditions like Erythema Multiforme.

Official documentation notes that severe or unusual skin changes may occur, which is information users should be aware of.


Q: What evidence exists for Nimesulid Canon's use in period pain?

Official therapeutic indications explicitly list primary dysmenorrhoea (period pain) as one of the approved uses for Nimesulide. This use is based on the drug’s established ability to treat acute pain and inflammation.


Q: Does Nimesulid Canon contain aspirin?

No, Nimesulid Canon contains Nimesulide as its active ingredient and does not contain aspirin (acetylsalicylic acid).

However, the drug is contraindicated (should not be used) in people with a history of hypersensitivity reaction to aspirin or other NSAIDs.


Q: Is there a generic version of Nimesulid Canon available?

The name 'Nimesulid Canon' is a brand or trade name. Nimesulide itself is the name of the active ingredient and is used as the generic name for the substance.


Q: What regulatory bodies have approved Nimesulid Canon?

The drug is authorized and regulated by the European Medicines Agency (EMA) for use as a second-line treatment across various member states of the European Union. Its use is also monitored by national health authorities.


Q: Are there any restrictions on driving while taking Nimesulid Canon?

Official warnings state that a user’s ability to drive or operate machinery may be impaired if they experience side effects that affect the central nervous system, such as dizziness or drowsiness (somnolence).


Q: Can Nimesulid Canon affect blood clotting?

Yes, official product information states that the drug can interfere with platelet function (a component of blood clotting).

For safety reasons, it is contraindicated in patients with severe coagulation (blood clotting) disorders.


Q: Is Nimesulid Canon effective for fever reduction?

Yes, official documents describing the drug's properties classify it as an agent with established antipyretic effects, meaning it can help reduce fever, in addition to its anti-inflammatory and pain-relieving actions.


Q: Is Nimesulid Canon banned in any European countries?

While the drug is authorized within the European Union under strict limitations set by the EMA, some individual EU countries have previously made national decisions to withdraw or severely restrict its availability due to specific concerns about hepatotoxicity risk.


Q: Can a person with asthma use Nimesulid Canon?

The drug is contraindicated in patients who have a history of hypersensitivity reactions, such as bronchospasm (a common symptom in asthma), that were previously triggered by aspirin or other NSAIDs.


Q: Is Nimesulid Canon used for chronic conditions?

The regulatory protocol for Nimesulide mandates that its use be limited to the shortest possible duration, with a systemic maximum of 15 days.

This limited duration of use means the drug is primarily intended for acute symptom relief and is not suited for continuous, long-term management of chronic conditions.


Q: Can Nimesulid Canon be used with Paracetamol?

Patients are generally advised in the official guidelines to refrain from using other analgesics during treatment. Co-administration with other substances considered potentially hepatotoxic (toxic to the liver), which includes Paracetamol, must be avoided due to the increased risk of liver issues.


Q: Are there known interactions between Nimesulid Canon and oral contraceptives?

Official documents contain general caution regarding potential interactions with other medicines. Since Nimesulide is metabolized in the liver, caution is advised when combining it with other medicines that are also metabolized by the liver or are potentially hepatotoxic.


Q: Does Nimesulid Canon affect sleep patterns?

Reported side effects include central nervous system effects such as dizziness and drowsiness (somnolence).

Any effects that influence the nervous system may indirectly affect a person's sleep patterns.


Q: Do food or milk affect how Nimesulid Canon is absorbed?

The official administration guidelines state that the oral forms of the medicine must be taken after a meal.

This condition of use may influence the rate of absorption and is part of the guidelines to help manage the risk of gastrointestinal side effects.


Q: What other common medicines should not be taken with Nimesulid Canon?

The official label warns of potential interactions with several classes of drugs. These include: anticoagulants (used to thin the blood), antiplatelet agents (like low-dose aspirin), other NSAIDs, and certain diuretics (water tablets).

Advertisements

How should Nimesulid Canon be stored and disposed of?

How to Store and Dispose of Nimesulide Canon

The storage and disposal requirements for Nimesulide are established in official government-approved labeling, such as the Summary of Product Characteristics (SmPC) in countries where the medicine is authorized.

Storage Conditions

  • Temperature and Protection: Oral formulations (tablets and granules) must be stored below 25 C and protected from light and moisture. Topical gel must not freeze.
  • Packaging: Keep the medicine in the original package to ensure protection and stability.
  • Child Safety: Like all medicines, it must be kept out of the sight and reach of children.

Disposal Requirements

  • Environmental Rule: Do not dispose of Nimesulide via wastewater or household waste.
  • Official Procedure: Unused or expired medicine must be disposed of in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nimesulid Canon found in:

A-Z Index: